-Bloomberg
InflaRx Submits Request For Emergency Use Authorization To US FDA For Vilobelimab For Treatment Of Critically Ill COVID-19 Patients
Company also earns FDA Fast Track designation for vilobelimab to treat critically ill COVID-19 patients
EUA submission based on Phase III results in critically ill COVID-19 patients, recently published in The